Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main inclusion criteria:~1. Female or male subjects with age between 6 and 18 years old.~2. Subjects with documented diagnosis of one of the three presentations of Attention Deficit Hyperactivity Disorder (ADHD) within one year by investigator assessment using Diagnostic \& Statistical Manual for Mental Disorders-Fifth Edition (DSM-5).~3. Both subjects and parents/guardians have provided their signed and dated informed consent form for the study.~Main exclusion criteria:~1. Subjects have received ADHD treatment for over 1 year or those who have received other ADHD treatment within 30 days prior to the study treatment initiation.~2. By investigator's evaluation, subjects are very anxious, tense or agitated.~3. Subjects known to be allergic to any ORADUR®-methylphenidate ingredients.~4. Subjects with an estimated intelligence quotient (IQ) \< 80.~5. Subjects are taking a concomitant medication (ex: Monoamine Oxidase Inhibitor (MAOI)) that is likely to interfere with safe administration of methylphenidate within 14 day prior to the study treatment initiation.~6. Subjects are joining other clinical studies and receiving any other investigational medical products within 30 days prior to the study treatment initiation.~7. Subjects have glaucoma (narrow angle glaucoma), on-going seizure disorder, or other psychotic disorder.~8. Subjects have chronic tics, Tourette's syndrome, or a family history of Tourette's syndrome.~9. Subjects have clinically significant gastrointestinal problems, including narrowing of the gastrointestinal tract.~10. Subjects/caregivers are (in the case of subjects whose parents/caregivers were to fill out the study questionnaires) with drug or alcohol abuse/dependence within the prior 6 months.~11. By the investigators' discretion, subjects with serious or unstable medical illness that will interfere with the evaluations of study efficacy and safety.~12. In the investigators' opinion, subjects cannot understand or follow the instructions given in the study.~13. Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Placebo First, then ORADUR® (Type: PLACEBO_COMPARATOR): Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
- ORADUR® First, then Placebo (Type: EXPERIMENTAL): ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)

Based on this trial design, predict the completion outcome and termination type (if applicable).